Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Fiala

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
Cancer Control : Journal of the Moffitt Cancer Center|December 22, 2025
Convenience Versus Continuity: A Pilot Study of Care Transfer to a Satellite Clinic for Patients With Plasma Cell DyscrasiasAngela M Vickroy, Margaret Kavanaugh, Jordan Smith, et al.
Journal of Clinical & Experimental Oncology|January 28, 2026
Efficacy of Interventions for Newly Diagnosed Multiple Myeloma: An Umbrella ReviewYimeng Li, Mengmeng Ji, Mark A Fiala, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 5, 2023
Venous Thromboembolism Risk in Patients With Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination With Lenalidomide and DexamethasoneAlexa J Loncharich, Mark A Fiala, Michael J Slade, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 22, 2017
Fresh or Cryopreserved CD34<sup>+</sup>-Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell TransplantationArmin Ghobadi, Mark A Fiala, Giridharan Ramsingh, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 29, 2024
Treatment Access among Younger Medicaid Beneficiaries with Multiple MyelomaMark A Fiala, Mengmeng Ji, Yi-Hsuan Shih, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2019
A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple MyelomaMark A Schroeder, Mark A Fiala, Eric Huselton, et al.
Cancer Medicine|November 21, 2022
Impact of the COVID-19 pandemic on breast, colorectal, lung, and prostate cancer stage at diagnosis according to raceJennifer Berrian, Ying Liu, Nkiruka Ezenwajiaku, et al.
Blood Advances|September 23, 2021
Machine learning-based scoring models to predict hematopoietic stem cell mobilization in allogeneic donorsJingyu Xiang, Min Shi, Mark A Fiala, et al.
Nature Communications|May 31, 2020
Evolution and structure of clinically relevant gene fusions in multiple myelomaSteven M Foltz, Qingsong Gao, Christopher J Yoon, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 12, 2017
Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin LymphomaPavan Kumar Bhamidipati, Mark A Fiala, Brenda J Grossman, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Cancer Control : Journal of the Moffitt Cancer Center|December 22, 2025
Convenience Versus Continuity: A Pilot Study of Care Transfer to a Satellite Clinic for Patients With Plasma Cell DyscrasiasAngela M Vickroy, Margaret Kavanaugh, Jordan Smith, et al.
Journal of Clinical & Experimental Oncology|January 28, 2026
Efficacy of Interventions for Newly Diagnosed Multiple Myeloma: An Umbrella ReviewYimeng Li, Mengmeng Ji, Mark A Fiala, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 5, 2023
Venous Thromboembolism Risk in Patients With Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination With Lenalidomide and DexamethasoneAlexa J Loncharich, Mark A Fiala, Michael J Slade, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 22, 2017
Fresh or Cryopreserved CD34<sup>+</sup>-Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell TransplantationArmin Ghobadi, Mark A Fiala, Giridharan Ramsingh, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 29, 2024
Treatment Access among Younger Medicaid Beneficiaries with Multiple MyelomaMark A Fiala, Mengmeng Ji, Yi-Hsuan Shih, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2019
A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple MyelomaMark A Schroeder, Mark A Fiala, Eric Huselton, et al.
Cancer Medicine|November 21, 2022
Impact of the COVID-19 pandemic on breast, colorectal, lung, and prostate cancer stage at diagnosis according to raceJennifer Berrian, Ying Liu, Nkiruka Ezenwajiaku, et al.
Blood Advances|September 23, 2021
Machine learning-based scoring models to predict hematopoietic stem cell mobilization in allogeneic donorsJingyu Xiang, Min Shi, Mark A Fiala, et al.
Nature Communications|May 31, 2020
Evolution and structure of clinically relevant gene fusions in multiple myelomaSteven M Foltz, Qingsong Gao, Christopher J Yoon, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 12, 2017
Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin LymphomaPavan Kumar Bhamidipati, Mark A Fiala, Brenda J Grossman, et al.
Pageof 8